Jakushitsu Genko

Jakushitsu Genko was a Zen adept of the Rinzai sect.
   
He is recognized for his asceticism, affability, flute playing, and poetry.

Perhaps his most notable attribution is 'Why pursue words when one truly seeks silence?'

Comments

Post a Comment

Popular posts from this blog

Bearpaw Scales Fast

Bearpaw scales fast. Amplifying their presence and forging ahead far and wide. Launching foreign e-commerce sites and appearing at cosmopolitan trade shows. Bearpaw has teamed up with Scalefast to open and launch websites in Canada (bearpawshoes.ca), Europe (bearpawshoes. eu ), and the United Kingdom (bearpawshoes.co. uk ). The new websites stay true to the organic and warm Bearpaw aesthetic. Nicolas Stehle , CEO at Scalefast, said: 'Bearpaw's undeniable commitment to comfort, sensibility, and customer care has made it a world-class lifestyle brand. We are delighted that Bearpaw chose Scalefast as its long-term partner to help scale its e-commerce abroad and bring the Bearpaw lifestyle to online shoppers around the world.' John Pierce, President of Bearpaw, said: 'Within the last couple of years, we have gained a significant global presence, and look forward to growing our international audience. While style and culture may differ from one anoth...
Read more

Blackstone Invests In Carrix

Blackstone invests in Carrix.     Funds associated with Blackstone Infrastructure Partners invested in Carrix, the biggest marine terminal operator in the U.S. and the Americas.      Carrix is the parent company of SSA Marine with collective operations at over 250 port and rail locations worldwide.  This includes 16 container terminals in Long Beach, Oakland, Seattle, Tacoma, Panama, Mexico, Chile, Colombia, and Vietnam.     Jon Hemingway of Carrix said: ‘We are happy that BIP has invested in Carrix and will be working with us to continue our on-going growth and development.  Along with its affiliates, BIP brings a network of highly skilled and experienced people, global relationships, ability in a diverse array of businesses, and myriad capabilities to apply.  When combined with our experience in the port industry and infrastructure development, we have broadened what our shareholders and directors can do to support Carrix an...
Read more

Merck Buys Peloton

Merck buys Peloton.     Merck buys Peloton Therapeutics for $1.05 billion.     Peloton's molecular therapy biotech treatments for patients with cancer and other non-oncology diseases are now in clinical trials.  Peloton is focused on developing treatments that target a pathway activated by low oxygen levels.     This deal builds out the Merck oncology pipeline, strengthening its presence in the field of renal cell carcinoma.  Merck’s blockbuster immunotherapy Keytruda, that helps turn the immune system against cancer cells, was approved last month in the United States.     Peloton will begin studying its lead drug, a kidney cancer treatment with the catchy code name PT2977, in a late-stage trial in the second half of 2019.  In earlier mid-stage trials, testing patients whose cancer had spread even after treatment with at least one therapy, 24% of patients treated with Peloton’s drug showed a 30% shrinkage of targeted lesions...
Read more